RxDoctor Payments DataLook up a doctor →

Jeremy Schmidt

Family · New Braunfels, TXNPI 1184892622

Payments from drug & device makers

$132,479in general payments, 2019–2025

Across 1,085 payments — averaging $122.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$73K
  • Lilly USA, LLC$40K
  • Mannkind Corporation$5K
  • Abbott$3K
  • Zealand Pharma US, Inc.$2K
  • Dexcom, Inc.$828
  • plus $8K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk306$73,046
Lilly USA, LLC205$40,093
Mannkind Corporation50$4,956
Abbott26$2,720
Zealand Pharma US, Inc.19$2,338
Dexcom, Inc.16$828
Bayer44$738
AstraZeneca(2 entities)39$725
Boehringer Ingelheim35$701
Amgen42$692
Corcept Therapeutics38$652
Medtronic13$372
Amneal Pharmaceuticals LLC18$320
Sanofi-aventis U.S. LLC17$291
Amarin Pharma, Inc.17$282
Esperion Therapeutics, Inc.17$276
Antares Pharma, Inc.14$206
SK Life Science, Inc.10$194
Insulet Corporation11$189
Madrigal Pharmaceuticals4$185
Recordati_rare_diseases_inc.11$179
BETA Bionics, Inc.10$173
Averitas Pharma Inc.8$169
Amylyx Pharmaceuticals, Inc.9$168
Xeris Pharmaceuticals, Inc.9$148
Currax Pharmaceuticals LLC14$144
Radius Health, Inc.7$139
Tandem Diabetes Care, Inc.3$130
Johnson & Johnson(2 entities)7$114
GRT US Holding, Inc.5$90
Cequr Corporation3$87
Sequel Med Tech, LLC4$85
Biohaven Pharmaceutical Holding Company Ltd.2$81
IBSA Pharma Inc.5$79
Otsuka America Pharmaceutical, Inc.4$75
Neurocrine Biosciences, Inc.3$72
Takeda Pharmaceuticals U.S.A., Inc.3$68
Teva Pharmaceuticals USA, Inc.4$67
Vistapharm, Inc.5$67
Ascendis Pharma Endocrinology Inc2$53
Acerus Pharmaceuticals Corporation3$49
Echosens North America, Inc.1$40
Pfizer2$34
Lifescan, Inc.2$30
Kowa Pharmaceuticals America, Inc.2$30
Halozyme Inc2$30
Aurinia Pharma U.S., Inc.1$28
GE HealthCare1$25
Mylan Specialty L.p.1$25
UCB, Inc.1$23
Ultragenyx Pharmaceutical Inc.1$22
AbbVie1$21
Paratek Pharmaceuticals, Inc.1$21
Soleno Therapeutics, Inc.1$19
Inspire Medical Systems, Inc.1$19
Lundbeck LLC1$17
Ascensia Diabetes Care US Inc.1$17
Endo Pharmaceuticals Inc.1$16
Indivior Inc.1$13
Bigfoot Biomedical Inc1$12

How this compares

$132,479 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Medicare billing

Part B allowed, 2024
$60,751
Medicare patients
210
Services billed
839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in New Braunfels

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →